Roche Holding said a combination of Lunsumio and Polivy significantly prolonged remission for patients with relapsed or refractory large B-cell lymphoma in a late-stage trial.
The Swiss pharmaceutical group said administering Lunsumio along with Polivy showed clinically a significant improvement in its primary endpoints of progression-free survival and objective response rate compared to other drugs in people with relapsed or refractory large B-cell lymphoma.
The results for Lunsumio, also known as mosunetuzumab, and Polivy, also known as polatuzumab vedotin, came as part of a phase 3 study. Roche said it would now submit results to global health authorities, including the Food and Drug Administration in the U.S.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.